Fig. 3From: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysisObserved lactate dehydrogenase values over time. Data are shown as mean (error bars, 95% confidence interval). BL baselineBack to article page